Compare Abeona Therapeutics Inc (ABEO) vs Sibanye Stillwater Ltd (SBSW) Price & Performance
Price performance
Price movement over the last 24 hours
Key statistics
Key statistics
Abeona Therapeutics Inc vs Sibanye Stillwater Ltd — how do they compare? Abeona Therapeutics Inc trades at $6.77 (market cap $373.32M), while Sibanye Stillwater Ltd trades at $8.25 (market cap $5.98B). The key difference: Sibanye Stillwater Ltd is far larger — about 16× Abeona Therapeutics Inc's market cap, and Sibanye Stillwater Ltd pays a 3.65% dividend while Abeona Therapeutics Inc pays none. Which is the better fit depends on your goals.
| ABEO | SBSW | |
|---|---|---|
Market Cap | $373.32M | $5.98B |
Sector | Health | Basic Materials |
52-Week High | $7.23 | $21.12 |
52-Week Low | $4.17 | $7.27 |
Enterprise Value | $228.22M | $7.60B |
Dividend Yield | — | 3.65% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
ABEO trades at $6.31, down 1.41% today, with a bullish technical outlook supported by moving averages. The company reported Q1 2026 results with revenue growth and beat EPS expectations, while maintaining strong profitability margins. Recent news highlights expansion of treatment centers and new cell therapy licensing.
Outlook remains positive with analyst consensus favoring Buy ratings (66.67%), though high RSI indicates potential near-term overbought conditions. Key risks include negative operating cash flow and reliance on new treatment adoption. Upside depends on continued commercial execution and pipeline advancements.
Sibanye Stillwater (SBSW) trades at $8.52, down 4.91% today, with a bearish technical signal and negative earnings trends. The company reported a net loss of $7.30 billion in 2024, though revenue remains substantial at $112.13 billion. Recent news highlights operational improvements, including a surge in EBITDA and management's debt reduction targets, but profitability challenges persist.
The outlook is mixed: low valuation multiples suggest potential upside if operational turnaround succeeds, but negative margins and high debt pose significant risks. Analyst sentiment leans bullish with 42.86% buy ratings, yet recent earnings misses and cash flow volatility warrant caution for investors.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Abeona Therapeutics Inc
Abeona Therapeutics develops gene and cell therapies for rare diseases. Its lead product, ZEVASKYN, is an FDA-approved therapy for recessive dystrophic epidermolysis bullosa (RDEB), a severe and life-threatening genetic skin disorder.
Read more on ABEO →About Sibanye Stillwater Ltd
Sibanye Stillwater Ltd is a South Africa-focused mining company. The Group currently owns and operates five underground and surface gold operations in South Africa: the Cooke, DRDGOLD, Driefontein, and Kloof operations in the West Witwatersrand region, and the Beatrix Operation in the southern Free State province. In addition to mining, the company owns and manages extraction and processing facilities at its operations, where gold-bearing ore is treated and beneficiated to produce gold dore. The gold dore is further refined at Rand Refinery into gold bars with a purity of at least 99.5% and is then sold on international markets. Sibanye holds a 44% interest in Rand Refinery, global refiners of gold, and the largest in Africa. Rand Refinery markets gold to customers around the world.
Read more on SBSW →
